AstraZeneca Pharma India surrenders factory license

AstraZeneca Pharma India Limited surrendered its factory license to the Department of Factories, Boilers, Industrial Safety and Health on June 3, 2026. The license, valid from December 14, 2023, to December 31, 2026, was surrendered for cancellation by an Administrative Committee of the Board of Directors. This move follows the company's earlier intimations to the stock exchanges regarding the exit from its manufacturing site and the surrender of the manufacturing license.

The approval to surrender the license was granted by the Administrative Committee of the Board of Directors. The company had previously informed the exchanges about its decision to exit the manufacturing site on June 21, 2024, and about the surrender of the manufacturing license on September 2, 2025.

The details of the surrendered license were submitted in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that the license was surrendered voluntarily and not withdrawn or suspended by the regulatory authority.

The table below summarizes the key details of the license surrender:

Sl. No.	Particulars	Details
1	Name of the regulatory or licensing authority	Department of Factories, Boilers, Industrial Safety and Health.
2	Brief details of the approval/license obtained/ withdrawn/ surrendered	The Company has surrendered its factory license, which was valid up to December 31, 2026, to the Department of Factories, Boilers, Industrial Safety and Health for cancellation.
3	Impact/relevance of such approval/license to the listed entity	Not applicable
4	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not applicable
5	Period for which such approval/license is/was valid	The license is valid for a period from December 14, 2023 to December 31, 2026.
6	Actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not applicable

The intimation was submitted by Tanya Sanish, Company Secretary & Compliance Officer of AstraZeneca Pharma India Limited. The company requested the stock exchanges to take the intimation on record.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.50%	-1.54%	+3.67%	-6.62%	-8.80%	+126.16%

AstraZeneca Pharma India Limited announced the resignation of two senior management personnel, Mr. Ayush Kumar Agarwal and Ms. Shikha Mirchandani Chatrath, who are leaving to pursue career opportunities outside the organization. The company disclosed that it is currently searching for suitable replacements to fill the vacant leadership positions. The resignations were intimated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Ayush Kumar Agarwal served as the Business Unit Director – Biopharmaceutical Business Unit. He will complete his handover period and be relieved from his duties by the close of business hours on June 12, 2026. Ms. Shikha Mirchandani Chatrath held the position of Director – Commercial Excellence, BD and Strategy. She is scheduled to complete her handover and exit the company by the close of business hours on August 3, 2026.

The details of the resignations were provided in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirmed that the term of appointment and brief profiles for the positions were not applicable as per the submitted annexure. The company thanked the executives for their contributions and wished them success in their future endeavours.

Resignation Details

Name	Designation	Date of Cession	Reason
Mr. Ayush Kumar Agarwal	Business Unit Director – Biopharmaceutical Business Unit	June 12, 2026	Resignation to pursue his career outside the Company
Ms. Shikha Mirchandani Chatrath	Director – Commercial Excellence, BD and Strategy	August 3, 2026	Resignation to pursue her career outside the Company